



## MULTIDISCIPLINARY SYMPOSIUM IN THORACIC ONCOLOGY

CHICAGO, IL – SEPTEMBER 14-16, 2017

Chicago Fairmont Hotel Chicago, IL

Steering Committee: Fred R. Hirsch, MD, PhD, Everett Vokes, MD  
Program Chairs: Jyoti D. Patel, MD, Heather Wakelee, MD

### Thursday, September 14, 2017

4:00 - 6:00 p.m.	Registration	
6:00 - 6:10 p.m.	Opening Ceremony and Welcome – Chicago Fairmont Hotel, Imperial Room F.R. Hirsch, E. Vokes, J. Patel	
6:10 - 7:30 p.m.	Keynote Addresses:	
6:10 - 6:30 p.m.	Beyond approved PD-1/PD-L1 strategies: Biomarkers besides PD-L1 and IO combinations Likely to change practice in the near term	Hossein Borghaei
6:30 - 6:50 p.m.	On the edge: IO toxicity management and use in patients with underlying autoimmunity	Matthew Hellmann
6:50 - 7:10 p.m.	The interplay of IO and radiation therapy	Roy Decker
7:10 - 7:30 p.m.	Value Frameworks in Cancer Care: A Patient Perspective	Janet Freeman-Daily
7:30 - 9:00 p.m.	<b><u>Dinner Symposium Sponsored by AstraZeneca</u></b> <b>The Role of Immunotherapy for the Management of Patients with Locally Advanced NSCLC</b>	



# Friday, September 15, 2017

7:00 a.m. - 5:00 p.m.	<b>Registration</b>	
8:00 - 9:00 a.m.	<b><u>Breakfast Symposium Sponsored by AstraZeneca</u></b>	
8:00 - 9:00 a.m.	<b><u>Breakfast in the registration area</u></b>	
9:00 - 9:05 a.m.	<b>Welcome</b> <b>F.R. Hirsch, E. Vokes, J. Patel, H. Wakelee</b> <b>Location: Imperial Room</b>	
	<b>Chairs: Fred Hirsch, Heather Wakelee</b>	
9:05 - 9:20 a.m.	Research and Policy Priorities in Tobacco Control	Stephanie Land
9:20 - 9:35 a.m.	Barriers to Widespread Lung Cancer Screening	James Mulshine
9:35 - 9:50 a.m.	Pulmonologists in the Era of Precision Oncology	Colin Gillespie
9:50 - 10:05 a.m.	Optimal tissue utilization in the molecular and IO era	Jeremy Segal
10:05 - 10:20 a.m.	Blood-based Biomarkers in Thoracic Oncology	Max Diehn
10:20 - 10:35 a.m.	Access to care, cost, and health disparities—shifting sands	Robert Winn
10:35 - 11:05 a.m.	Oligometastatic disease and synchronous primaries – optimal approaches	Puneeth Iyengar Osman Ahmed Jessica Donington
11:05 - 11:30 a.m.	<b>Break</b>	
11:30 a.m. - 1:00 p.m.	<b><u>Highlighted Oral Session 1</u></b> <b>Location: Imperial Room</b> <b>Session Chairs: Mary Jo Fidler &amp; Jyoti Patel</b>	
11:30 - 11:55 a.m.	How BAPI Modulates Gene-Environment Interaction In Carcinogenesis and Renders Tumor Cells Resistant to Chemotherapy	Michele Carbone
11:55 a.m. - 12:03 p.m.	<b>OA01.02</b> Novel Use of an Electronic Medical Record to Monitor Performance of a Lung Cancer Screening Program	Cherie Erkmen
12:03 - 12:11 p.m.	<b>OA01.03</b> Attrition Rate in Community-Based Lung Cancer Screening: One and Done	Alexander Carlson

12:11 - 12:19 p.m.	<b>OA01.04</b> A Comparability Study Verifying the Analytic Performance of a Blood-based Gene Expression Classifier to Identify Benign Pulmonary Nodules	Lyssa Friedman
12:19 - 12:26 p.m. Joy Feliciano	<b>Discussant abstracts OA01.02, OA01.03, OA01.04:</b>	
12:26 - 12:34 p.m.	<b>OA01.05</b> Radiation Dose and Fractionation for Limited-Stage Small Cell Lung Cancer: A Survey of US Radiation Oncologists on Practices	Matthew Farrell
12:34 - 12:50 p.m.	<b>Discussant abstract OA01.05</b>	Steven Chmura
1:00 - 2:30 p.m.	<b><u>Lunch Symposia Sponsored by Takeda</u></b>	
1:00 - 2:30 p.m.	<b><u>Lunch in the registration area</u></b>	
2:30 - 3:15 p.m.	<b>Education Session 1A &amp; 1B</b>	
2:30 - 3:15 p.m.	<b><u>Breakout Session 1A: Thoracic surgery at the “cutting edge”</u></b> <b>Location: Imperial Room</b> <b>Chair: Malcolm DeCamp</b>	
2:30 - 2:40 p.m.	Multiple lung nodules and GGOs—When to cut?	Malcolm DeCamp
2:40 - 2:50 p.m.	Staging updates invasive vs radiographic	Linda Martin
2:50 - 3:00 p.m.	Complex resection in pleural diseases (mesothelioma/thymic)	Linda Martin
3:00 - 3:15 p.m.	<b>Discussion</b>	
2:30 - 3:15 p.m.	<b><u>Breakout Session 1B: Collateral damage in a new era of lung cancer treatment</u></b> <b>Location: Gold Room</b> <b>Chair: Ken Rosenzweig</b>	
2:30 - 2:40 p.m.	Cardio-oncology issues	Cliff Robinson
2:40 - 2:50 p.m.	Toxicity concerns with targeted and novel therapies	Ken Rosenzweig
2:50 - 3:00 p.m.	Protons for thoracic indications to reduce toxicity	Jim Urbanic
3:00 - 3:15 p.m.	<b>Discussion</b>	
3:15 - 4:00 p.m.	<b>Education Session 2A &amp; 2B</b>	

<b>3:15 - 4:00 p.m.</b>	<b><u>Breakout Session 2A: Team Based Care in Oncology</u></b> <b>Location: Imperial Room</b> <b>Chair: Kavitha Ramchandran</b>	
<b>3:15 - 3:25 p.m.</b>	Challenges and Opportunities of Team Based Care	David Gerber
<b>3:25 - 3:35 p.m.</b>	Symptom Management Partnerships	Kavitha Ramchandran Alison Tisch
<b>3:25 - 3:45 p.m.</b>	Shared Goal Setting for Elderly Patients with Lung Cancer	Monica Malec
<b>3:45 - 4:00 p.m.</b>	<b>Discussion</b>	
<b>3:15 - 4:00 p.m.</b>	<b><u>Breakout Session 2B: In the Perioperative Setting</u></b> <b>Location: Gold Room</b> <b>Chair: Jamie Chافت</b>	
<b>3:15 - 3:25 p.m.</b>	Neoadjuvant/Adjuvant Updates	Jamie Chافت
<b>3:25 - 3:35 p.m.</b>	Importance of Lymph node sampling	Ray Osarogiagbon
<b>3:35 - 3:45 p.m.</b>	Surveillance imaging	Leah Backhus
<b>3:45 - 4:00 p.m.</b>	<b>Discussion</b>	
<b>4:00 - 4:30 p.m.</b>	<b>Break</b>	
<b>4:30 - 4:58 p.m.</b>	<b>Education Session 3A &amp; 3B</b>	
<b>4:30 - 4:58 p.m.</b>	<b><u>Session 3A</u></b> <b>Location: Imperial Room</b> <b>Chair: Larry Feldman</b>	
<b>4:30 - 4:38 p.m.</b>	<b>3A.01</b> Efficacy of Programmatic Combined Stereotactic Ablative Radiotherapy and Anti- PD-1 Therapy in Advanced Lung Cancer: A Retrospective Analysis.	Aparna Hegde
<b>4:38 - 4:46 p.m.</b>	<b>3A.02</b> Major Drivers of Combined Modality Therapy for Limited-Stage Small Cell Lung Cancer in the United States National Cancer	Stephen Chun
<b>4:46 - 4:58 p.m.</b>	<b>Discussant abstracts 3A.01, 3A.02</b>	Larry Feldman
<b>4:30 - 4:58 p.m.</b>	<b><u>Session 3B</u></b> <b>Chair: Tim Kruser</b> <b>Location: Gold Room</b>	

4:30 - 4:38 p.m.	<b>3B.01</b> Hematologic Malignancies in Lung Cancer Survivors – the Contribution of Radiation Therapy	Sarit Appel
4:38 - 4:58 p.m.	<b>Discussant abstract 3B.01</b>	Tim Kruser
5:05 - 5:45 p.m.	<b>Education Session 4A &amp; 4B</b>	
5:05 - 5:45 p.m.	<b><u>Session 4A</u></b> <b>Location: Imperial Room</b> <b>Chair: Fred Hirsch</b>	
5:05 - 5:13 p.m.	<b>4A.02</b> Confirmation of Pathological Diagnosis in Lung Cancer Patients by ctDNA Detection through Ultra-Deep Sequencing	Geng Tian
5:13 - 5:21 p.m.	<b>4A.03</b> Predictive Utility of c-reactive Protein (CRP) in Advanced Stage Lung Cancer Treated with Anti-Programmed Cell Death-1 (PD-1)	Abdul Rafah Naqash
5:21 - 5:45 p.m.	<b>Discussant abstracts 4A.02, 4A.03</b>	Fred Hirsch
5:05 - 5:45 p.m.	<b><u>Session 4B</u></b> <b>Location: Gold Room</b> <b>Chair: Ray Osarogiagbon</b>	
5:05 - 5:13 p.m.	<b>4B.01</b> Lung Cancer Patients Migrate to Seek Better Care	Danh Pham
5:13 - 5:21 p.m.	<b>4B.02</b> Increasing Survival in Stage IV NSCLC in Academic Versus Community Based Centers in the National Cancer Database	Sendhilnathan Ramalingam
5:21 - 5:29 p.m.	<b>4B.03</b> Prospective Evaluation of Multidisciplinary Lung Cancer Care: Timeliness, Thoroughness, and Patient/Caregiver Perspectives	Matthew Smeltzer
5:29 - 5:45 p.m.	<b>Discussant abstracts 4B.01, 4B.02, 4B.03</b>	Ray Osarogiagbon
5:50 - 6:35 p.m.	<b><u>Highlighted Oral Abstract Session 2</u></b> <b>Location: Imperial Room</b> <b>Chairs: Nisha Mohindra &amp; Philip Bonomi</b>	
5:50 - 5:58 p.m.	<b>OA02.01</b> Comparison of iRECIST to RECIST1.1 for Following Response to Anti-PD1 Therapy in Patients with Non-Small Cell Lung Cancer	Sharyn Katz

5:58 - 6:06 p.m.	<b>OA02.02</b> Long Term Follow up of Ipilimumab and Targeted Therapy for Metastatic EGFR/ALK Lung Cancer	Anna Chalmers
6:06 - 6:14 p.m.	<b>OA02.03</b> Potential Predictors of Pembrolizumab Associated Pneumonitis: A Retrospective Review of the HCRN LUN 14-179 Trial.	Shahid Ahmed
6:14 - 6:26 p.m.	<b>OA02.04</b> The Cost and the Benefit: Front-Line Immunotherapy For Non-Small Cell Lung Cancer	Christine Bestvina
6:26 - 6:35 p.m.	<b>Discussant abstracts OA02.01, OA02.02, OA02.03, OA02.04</b>	Hossein Borghaei
6:35 - 7:30 p.m.	<b><u>Poster Viewing and Reception</u></b>	
7:30 - 9:30 p.m.	<b><u>Dinner Symposium Sponsored by Bristol-Meyers Squibb, Genentech, Inc. and Merck &amp; Co., Inc.</u></b> Location: Gold Room	
7:30 - 9:30 p.m.	<b><u>Dinner Symposium Sponsored by AstraZeneca</u></b> Location: Imperial Room	

# Saturday, September 16, 2017

7:00 a.m. - 1:00 p.m.	Registration	
6:30 - 8:00 a.m.	<u>Breakfast Symposium Sponsored by AstraZeneca – New Options and Evolving Strategies for Hitting the Target in EGFR-Mutant NSCLC</u>	
7:00 - 8:00 a.m.	<u>Breakfast in the registration area</u>	
8:00 - 8:45 a.m.	Tumor Board	Moderated by Tim Murgu
	Faculty: Jeff Mueller, Jessica Donington, Tim Kruser, Doug Arenberg, Tom Hensing, Heather Wakelee	
8:45 - 10:15 a.m.	<u>Highlighted Oral Session 3</u> Imperial Room Chairs: Tom Hensing & Matt Steliga	
8:45 - 8:53 a.m.	<b>OA03.01</b> Outcomes of Integrating Smoking Cessation Counseling in a Lung Cancer Screening Program	Andrew Nagy
8:53 - 9:01 a.m.	<b>OA03.02</b> An Intervention Study to Reduce Black-White Treatment Disparities in Early Stage Non-Small Cell Lung Cancer	Paul Walker
9:01 - 9:09 a.m.	<b>OA03.03</b> Community Network Lung Cancer Screening Experience Underrepresents Medically Underserved and Geographically Remote Individuals	Bretta McCall
9:09 - 9:21 a.m.	<b>Discussant abstracts OA03.01, OA03.02, OA03.03</b>	Matthew Steliga
9:21 - 9:29 a.m.	<b>OA03.04</b> Radiation Therapy Before Anti-PD1 Therapy Not Associated with Survival Difference; Single Institution Retrospective Review	Christopher Strouse
9:29 - 9:37 a.m.	<b>OA03.05</b> Tocilizumab for the Management of Immune Mediated Adverse Events Secondary to PD-1 Blockade: Overall Survival Analysis	Aparna Hegde
9:37 - 9:49 a.m.	<b>Discussant abstracts OA03.04, OA03.05</b>	Heather Wakelee

<b>9:49 - 10:01 a.m.</b>	<b>OA03.06</b> Overall Survival and Forced Vital Capacity in the LUME-Meso Study of Nintedanib + Pemetrexed/Cisplatin in Patients with Mesothelioma	Jose Barrueco
<b>10:01 - 10:09 a.m.</b>	<b>OA03.07</b> Dabrafenib and Trametinib Combination Therapy versus Docetaxel in Previously Treated Metastatic NSCLC: An Adjusted Indirect Comparison	Medha Sasane
<b>10:09 - 10:17 a.m.</b>	<b>OA03.08</b> Activity of Ensartinib after Second Generation Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitors (TKI)	Leora Horn
<b>10:17 - 10:30 a.m.</b>	<b>Discussant abstracts OA03.06, OA03.07, OA03.08</b>	Tom Stinchcombe
<b>10:30 - 10:45 a.m.</b>	<b>Break</b>	
<b>10:45 - 12:00 p.m.</b>	<b><u>Year in Review</u></b> <b>Session chair: Everett Vokes</b>	
<b>10:45 - 11:00 a.m.</b>	Beyond EGFR and ALK	Mary Jo Fidler
<b>11:00 - 11:15 a.m.</b>	Staging Updates – AJCC updates	Sanja Dacic
<b>11:15 - 11:30 a.m.</b>	Debate: Patients with EGFR mutation NSCLC should postpone brain radiation for brain metastasis	
<b>11:15 - 11:22 a.m.</b>		Pro: Lecia Sequist
<b>11:22 - 11:29 a.m.</b>		Con: Laurie Gaspar
<b>11:30 - 11:45 a.m.</b>	Debate: All patients with NSCLC Should Receive Immunotherapy 1 <sup>st</sup> Line	
<b>11:30 - 11:37 a.m.</b>		Pro: Jyoti Patel
<b>11:37 - 11:44 a.m.</b>		Con: John Heymach
<b>11:45 a.m. - noon</b>	Stage III NSCLC-current status, next steps	Everett Vokes
<b>Noon</b>	<b>Closing Remarks: F.R Hirsch, E. Vokes, J. Patel, H. Wakelee</b>	